Nuvation Bio Inc.: directors' dealings · United States · SEC (Form 4)

About Nuvation Bio Inc.

Nuvation Bio Inc. is a United States-based biopharmaceutical company listed on the NYSE/NASDAQ market, with corporate headquarters in New York, United States. Founded in 2018 by David Hung, M.D., a well-known biopharma executive and former founder of Medivation, the company was built around a strategy of developing and acquiring differentiated oncology assets aimed at areas of high unmet medical need. Its model is more focused than that of a broad diversified pharma company: Nuvation Bio is positioning itself as a specialized oncology player, relying on scientifically distinct programs with the potential to create both clinical and commercial value. The company’s core business centers on a small but strategically important pipeline. Its lead asset is taletrectinib, marketed in the United States as IBTROZI for certain advanced ROS1-positive non-small cell lung cancer patients. This product is the key inflection point in the company’s evolution, because it moved Nuvation Bio from a development-stage biotech toward a commercial-stage company in 2025. Beyond IBTROZI, the pipeline includes safusidenib, a brain-penetrant IDH1 inhibitor, NUV-1511, an innovative drug-drug conjugate designed for targeted cancer treatment, and NUV-868, a BD2-selective BET inhibitor. Together, these programs reflect a research strategy centered on mechanistically differentiated oncology assets rather than a large number of early-stage bets. From a competitive standpoint, Nuvation Bio operates in one of the most challenging and crowded segments of healthcare. It competes with both specialized biotech companies and larger pharmaceutical firms with established oncology franchises. Its relative advantage lies in the scientific profile of its programs, the experience of its management team, and its focus on high-need therapeutic niches. At the same time, as with most mid-cap biotech names, the company remains exposed to clinical, regulatory, commercialization, and financing risk, and its valuation will continue to depend heavily on execution and data readouts. Recent developments have strengthened the investment case around the lead asset. In 2025, the FDA approved IBTROZI for advanced ROS1-positive lung cancer, creating the company’s first commercial revenue stream. In 2026, Nuvation Bio announced FDA acceptance of a supplemental filing intended to update efficacy information on the label, and the drug was added to NCCN guideline recommendations for certain central nervous system cancer-related use cases. The company also signed an exclusive licensing agreement with Eisai for Europe and additional territories outside the United States, China, and Japan, expanding the potential geographic footprint of taletrectinib. For international investors, Nuvation Bio is best viewed as an oncology transition story: a U.S.-listed biotech with an emerging commercial product, an expanding geographic opportunity, and a pipeline that still provides meaningful upside optionality.